JP7542309B2 - 多孔性賦形剤を含む経鼻用医薬組成物 - Google Patents

多孔性賦形剤を含む経鼻用医薬組成物 Download PDF

Info

Publication number
JP7542309B2
JP7542309B2 JP2019516293A JP2019516293A JP7542309B2 JP 7542309 B2 JP7542309 B2 JP 7542309B2 JP 2019516293 A JP2019516293 A JP 2019516293A JP 2019516293 A JP2019516293 A JP 2019516293A JP 7542309 B2 JP7542309 B2 JP 7542309B2
Authority
JP
Japan
Prior art keywords
active agent
composition
testosterone
porous excipient
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019516293A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517590A (ja
JP2019517590A5 (enExample
Inventor
クラウディア マテルン
Original Assignee
エム エ ペ ファルマ アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エム エ ペ ファルマ アクチェンゲゼルシャフト filed Critical エム エ ペ ファルマ アクチェンゲゼルシャフト
Publication of JP2019517590A publication Critical patent/JP2019517590A/ja
Publication of JP2019517590A5 publication Critical patent/JP2019517590A5/ja
Priority to JP2022067716A priority Critical patent/JP7571078B2/ja
Application granted granted Critical
Publication of JP7542309B2 publication Critical patent/JP7542309B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Ceramic Engineering (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
JP2019516293A 2016-06-03 2017-06-02 多孔性賦形剤を含む経鼻用医薬組成物 Active JP7542309B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022067716A JP7571078B2 (ja) 2016-06-03 2022-04-15 多孔性賦形剤を含む経鼻用医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345369P 2016-06-03 2016-06-03
US62/345,369 2016-06-03
PCT/IB2017/053288 WO2017208209A1 (en) 2016-06-03 2017-06-02 Nasal pharmaceutical compositions with a porous excipient

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022067716A Division JP7571078B2 (ja) 2016-06-03 2022-04-15 多孔性賦形剤を含む経鼻用医薬組成物

Publications (3)

Publication Number Publication Date
JP2019517590A JP2019517590A (ja) 2019-06-24
JP2019517590A5 JP2019517590A5 (enExample) 2020-07-16
JP7542309B2 true JP7542309B2 (ja) 2024-08-30

Family

ID=59078127

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019516293A Active JP7542309B2 (ja) 2016-06-03 2017-06-02 多孔性賦形剤を含む経鼻用医薬組成物
JP2022067716A Active JP7571078B2 (ja) 2016-06-03 2022-04-15 多孔性賦形剤を含む経鼻用医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022067716A Active JP7571078B2 (ja) 2016-06-03 2022-04-15 多孔性賦形剤を含む経鼻用医薬組成物

Country Status (12)

Country Link
US (1) US11903951B2 (enExample)
EP (1) EP3463375A1 (enExample)
JP (2) JP7542309B2 (enExample)
KR (1) KR102387241B1 (enExample)
CN (1) CN109803663A (enExample)
AU (1) AU2017274649B2 (enExample)
CA (1) CA3026041A1 (enExample)
EA (1) EA201892595A1 (enExample)
MX (1) MX389588B (enExample)
SG (1) SG11201810628XA (enExample)
WO (1) WO2017208209A1 (enExample)
ZA (1) ZA201808551B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3050361A1 (en) 2017-01-20 2018-07-26 M et P Pharma AG Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
CN111902188A (zh) 2018-01-11 2020-11-06 马特恩制药股份公司 脱髓鞘疾病的治疗
CN110545795B (zh) * 2018-01-22 2021-02-26 北京茵诺医药科技有限公司 用于靶向活化cd44分子的水凝胶纳米载体递送系统、其制备方法和用途
US20220062165A1 (en) 2018-04-17 2022-03-03 M et P Pharma AG Compositions and methods for intranasal delivery of pregnenolone
WO2020037236A1 (en) 2018-08-17 2020-02-20 Massachusetts Institute Of Technology Degradable polymers of a cyclic silyl ether and uses thereof
WO2021096591A1 (en) 2019-11-15 2021-05-20 Massachusetts Institute Of Technology Functional oligomers and functional polymers including hydroxylated polymers and conjugates thereof and uses thereof
JP2023504876A (ja) * 2019-12-06 2023-02-07 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 薬物組成物、キット及びその応用
PE20230382A1 (es) 2020-05-18 2023-03-06 Orexo Ab Nueva composicion farmaceutica para administracion de farmacos
JP2021000481A (ja) * 2020-09-15 2021-01-07 株式会社三洋物産 遊技機
JP2021000484A (ja) * 2020-09-15 2021-01-07 株式会社三洋物産 遊技機
JP2021000483A (ja) * 2020-09-15 2021-01-07 株式会社三洋物産 遊技機
CN112263546B (zh) * 2020-09-29 2021-08-10 南京大学 通过鼻腔给药的佐匹克隆混悬液纳米制剂及其制备方法
EP4284854A1 (en) 2021-02-01 2023-12-06 Massachusetts Institute of Technology Reprocessable compositions
CN112972428B (zh) * 2021-03-09 2022-03-08 石河子大学 两性离子聚合物膜包覆的介孔硅基药物载体及制备方法
CN113456576B (zh) * 2021-06-28 2022-09-16 华中科技大学 纳米材料用于制备鼻腔纳米制剂脑靶向递送肠道药物应用
IL313016A (en) 2021-11-25 2024-07-01 Orexo Ab A pharmaceutical preparation that includes adrenaline
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
KR20240167901A (ko) * 2022-04-01 2024-11-28 에날레어 테라퓨틱스 인크. 호흡 자극제 비강 제형
CN115505052B (zh) * 2022-08-23 2023-05-23 安徽普利药业有限公司 一种β-环糊精衍生物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010505578A (ja) 2006-10-13 2010-02-25 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 切り換え可能な関節拘束システム
JP2014513147A (ja) 2011-05-13 2014-05-29 トリメル バイオファーマ エスアールエル 経鼻投与用の低投薬濃度テストステロンゲル製剤および無オルガズム症または性的欲求低下障害を治療するためのその使用
JP2014515038A (ja) 2011-05-15 2014-06-26 トリメル バイオファーマ エスアールエル 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
WO2016041992A1 (en) 2014-09-15 2016-03-24 Grace Gmbh & Co. Kg Active-loaded particulate materials for topical administration

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002597A (en) 1989-04-03 1991-03-26 Invent Ag Aerodynamic filter
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
DE19701912C1 (de) 1997-01-10 1998-05-14 Jenapharm Gmbh Injizierbares Implantat
DE10064950A1 (de) 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropes Nasenspray
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US7563451B2 (en) * 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
DK1530965T3 (da) * 2003-11-11 2006-07-17 Mattern Udo Kontrolleret frigivelsesleveringssystem til nasal applikation
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
EP1933811A2 (en) 2005-09-30 2008-06-25 Alza Corporation Banded controlled release nanoparticle active agent formulation dosage forms and methods
ES2358619T3 (es) * 2006-10-04 2011-05-12 M & P PATENT AKTIENGESELLSCHAFT Sistema de administración de liberación controlada para aplicación nasal de neurotransmisores.
US8258137B2 (en) * 2008-01-29 2012-09-04 Katholieke Universiteit Leuven Process for release of biologically active species from mesoporous oxide systems
MX356209B (es) * 2008-09-23 2018-05-18 Laboratory Skin Care Inc Partículas de fosfato de calcio nanoporosas, esféricas, rígidas, uniformes cargadas de agente activo y métodos para su fabricación y su uso.
US8778401B2 (en) * 2008-10-28 2014-07-15 Agency For Science, Technology And Research Mesoporous material excipients for poorly aqueous soluble ingredients
US20130040922A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
ITTO20111242A1 (it) * 2011-12-30 2013-07-01 Miso S R L Composizioni per il trattamento di patologie delle mucose
EP2911690A1 (en) * 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
WO2014076569A2 (en) * 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
US20150290217A1 (en) * 2012-11-21 2015-10-15 Trimel Biopharma Srl Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt
EP3065717A1 (en) 2013-11-04 2016-09-14 Biopharmx, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers
KR20180032644A (ko) 2015-08-04 2018-03-30 인큐팜 그룹 센디리안 버하드 코 조성물
US20180250656A1 (en) 2015-09-09 2018-09-06 King Abdullah University Of Science And Technology Functionalized sio2 microspheres for extracting oil from produced water
EP3229549B1 (en) * 2016-04-08 2018-11-21 Panasonic Intellectual Property Corporation of America Procedures for grouping wearable devices with lte master ues
CA3050361A1 (en) 2017-01-20 2018-07-26 M et P Pharma AG Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010505578A (ja) 2006-10-13 2010-02-25 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 切り換え可能な関節拘束システム
JP2014513147A (ja) 2011-05-13 2014-05-29 トリメル バイオファーマ エスアールエル 経鼻投与用の低投薬濃度テストステロンゲル製剤および無オルガズム症または性的欲求低下障害を治療するためのその使用
JP2014515038A (ja) 2011-05-15 2014-06-26 トリメル バイオファーマ エスアールエル 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
WO2016041992A1 (en) 2014-09-15 2016-03-24 Grace Gmbh & Co. Kg Active-loaded particulate materials for topical administration

Also Published As

Publication number Publication date
AU2017274649A1 (en) 2019-01-17
JP2019517590A (ja) 2019-06-24
CN109803663A (zh) 2019-05-24
MX389588B (es) 2025-03-20
CA3026041A1 (en) 2017-12-07
JP2022092061A (ja) 2022-06-21
WO2017208209A1 (en) 2017-12-07
KR102387241B1 (ko) 2022-04-15
EA201892595A1 (ru) 2019-06-28
JP7571078B2 (ja) 2024-10-22
US11903951B2 (en) 2024-02-20
KR20190027366A (ko) 2019-03-14
US20180008615A1 (en) 2018-01-11
ZA201808551B (en) 2025-05-28
EP3463375A1 (en) 2019-04-10
SG11201810628XA (en) 2018-12-28
AU2017274649B2 (en) 2023-02-02
MX2018014906A (es) 2019-08-21

Similar Documents

Publication Publication Date Title
JP7571078B2 (ja) 多孔性賦形剤を含む経鼻用医薬組成物
JP6433490B2 (ja) シリカハイドロゲルコンポジット
JP2019517590A5 (enExample)
AbouAitah et al. pH-controlled release system for curcumin based on functionalized dendritic mesoporous silica nanoparticles
EP1406593A2 (en) Biodegradable polymer compositions, compositions and uses related thereto
Choudhari et al. Mesoporous silica drug delivery systems
CN110603034A (zh) 一种适于肺、鼻、舌下和/或咽递送的，负载有至少一种生物活性化合物的多孔二氧化硅粒子的制造方法
JP6207291B2 (ja) 外用剤用組成物
Pattnaik et al. Mesoporous silica molecular sieve based nanocarriers: transpiring drug dissolution research
Haidary et al. Effect of coatings and surface modification on porous silicon nanoparticles for delivery of the anticancer drug tamoxifen
CN101166520B (zh) 用于提高药物制剂溶解性的溶剂体系
CN107982239A (zh) 疏水性药物晶体为模板的蛋白基非球形微囊及制备方法
EP3946257B1 (en) A delivery system comprising silicon-containing material
JP6354905B2 (ja) ゲル組成物、およびゲル組成物の製造方法
JP7158039B2 (ja) ゾル－ゲル／ヒドロゲル治療薬送達システム及びその方法
CN105030732A (zh) 壳聚糖包封液晶纳米粒所得微球及其制备方法
JP2001055323A (ja) 粉末状経鼻投与用組成物
EA043077B1 (ru) Назальные фармацевтические композиции с пористым наполнителем
JP2008266178A (ja) 経粘膜吸収用組成物
JP2023532778A (ja) シリカハイドロゲルコンポジットおよびその使用
Thombre et al. Domperidone loaded Caesalpinia pulcherrima galactomannan-based microspheres for nasal administration: In-vitro and In-vivo studies.
Latifi et al. Preparation and evaluation of risperidone slow-release injectable microspheres using chitosan
JP2025531248A (ja) カンナビノイドの鼻腔内送達
JP2004238372A (ja) 鼻腔又は口腔用製剤
TW201242969A (en) A pharmaceutical composition which improves the solubility and its preparation method

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220415

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220415

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220427

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220519

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220523

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220624

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240820

R150 Certificate of patent or registration of utility model

Ref document number: 7542309

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150